MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Monday reported a loss of $11.9 million in its first quarter.
On a per-share basis, the Mountain View, California-based company said it had a loss of 23 cents.
The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.
The biopharmaceutical company posted revenue of $8.3 million in the period, which missed Street forecasts. Five analysts surveyed by Zacks expected $11.4 million.
ChemoCentryx shares have climbed 23% since the beginning of the year. In the final minutes of trading on Monday, shares hit $13.41, a rise of 20% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI